Table 2.
Neurocognitive tests, baseline and change to month 6
| Baseline |
Change to month 6 |
||||
|---|---|---|---|---|---|
| Mean | ±1 SD | Mean | SE | P value | |
| QNPZ-5 | −0.68* | ±0.78 | 0.17 | 0.05 | <0.001 |
| Test z scoresa | |||||
| GPB | −0.26* | ±1.20 | 0.25 | 0.09 | <0.001 |
| CT1 | −0.52* | ±1.24 | 0.28 | 0.10 | <0.001 |
| CT2 | −0.00 | ±0.99 | 0.18 | 0.07 | <0.001 |
| TG | −1.64* | ±1.75 | 0.11 | 0.10 | 0.15 |
| FT | −0.98* | ±1.10 | 0.03 | 0.09 | 0.68 |
| Raw tests scores | |||||
| GPB (s) | 72.5 | ±26.3 | −3.8 | 1.5 | <0.001 |
| CT1 (s) | 47.5 | ±19.0 | −3.8 | 1.3 | <0.001 |
| CT2 (s) | 93.3 | ±32.6 | −5.1 | 2.0 | <0.001 |
| TG (s) | 11.9 | ±2.1 | −0.1 | 0.1 | 0.19 |
| FT (taps) | 39.3 | ±7.9 | 0.1 | 0.6 | 0.90 |
The QNPZ-5 score, individual test z scores, and raw test scores at baseline, and their change to month 6 are shown for 258 participants, pooled across the intermittent ART and continuous ART treatment groups. At baseline, the mean QNPZ-5 score and mean z scores for four of the five tests were below 0, denoting below-average performance compared with a healthy reference population. The QNPZ-5 score and individual test z scores increased from baseline to month 6; see also Fig. 1. There was no evidence for a treatment difference in mean change in QNPZ-5 or any of the z scores
CT Color Trails test, FT Finger Tapping test (nondominant hand), GPB Grooved Pegboard test (dominant hand), QNPZ-5 quantitative neurocognitive performance z score, TG Timed Gait test
P<0.001, mean z scores<0 (two-sided t test)
z scores were calculated with reference distributions (matched for education [all tests], age [GPB, CT, and FT], gender [GPB and FT], and race/ethnicity [GPB and FT]). Thirty-five participants (13.6 %) had NCI at baseline, defined as z scores<−2 in at least two cognitive ability domains, and the same number had NCI at month 6. Of those who were impaired at baseline, 16 participants (46 %) were not impaired at month 6, and vice versa